The Alzheimer’s Association, the American College of Radiology (ACR), the American Society of Neuroradiology (ASNR), the Department of Biostatistics, Brown University School of Public Health and the Critical Path Institute, along with other clinical research and imaging experts, has launched the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET).
Over six million Americans are living with Alzheimer’s disease (AD) or a related dementia. The field is entering a new phase of treatment and care with more than 140 AD therapies being tested in clinical trials and some currently under regulatory review. The Alzheimer’s Association convened a group of clinical research and imaging experts in 2021 to develop a network that evaluates the longitudinal outcomes of patients treated with novel FDA-approved AD therapies in real-world settings. In August 2022, the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) was launched.
ALZ-NET is a provider-enrolled network that collects real-world clinical and imaging data from patients being evaluated for or being treated with novel FDA-approved AD therapies. Novel FDA-approved therapies for AD are drugs that have received approval as treatments for Alzheimer's disease (AD) from the U.S. Food and Drug Administration since 2021. ALZ-NET is a resource for evidence gathering, information sharing and education across clinical and research communities, encouraging innovative, inclusive research and supporting opportunities to improve care.
The Alzheimer's Network for Treatment and Diagnostics is approved by the Centers for Medicare and Medicaid Services (CMS) as a Coverage with Evidence Development (CED) study and can be used as a pathway to Medicare coverage for anti-amyloid Alzheimer's therapies that have received traditional (full) FDA approval. This currently includes Leqembi (lecanemab), an anti-amyloid Alzheimer's disease treatment that has traditional FDA approval.
ALZ-NET is led by a team of co-principal investigators (Co-PIs) that have extensive experience in clinical research of Alzheimer’s disease and related dementia (ADRD). The Co-PIs have assembled a multidisciplinary group of industry respected and published individuals to form an advisory committee. This advisory committee serves to provide expertise and guidance in their respected domain as it pertains to dementia care and/or clinical research. Under the direction of the Co-PIs, ALZ-NET is ideally suited for the ongoing development, conduct, and output of ALZ-NET.
Steering Committee Oversight |
Workgroups and Subcommittees |
|
| A steering committee supports the scientific vision of ALZ-NET by monitoring progress against established timelines, evaluating scientific program initiatives, ensuring publication and dissemination of data, and approving budgets while monitoring financial compliance. | The steering committee creates workgroups and subcommittees as needed to perform additional functional roles. Established subcommittees include, but are not limited to, a Data Access and Publications Committee, a Communications and Recruitment Committee, an Imaging Committee, and a Data Management Committee. |
